Ray Dalio Legend Biotech Corp Transaction History

Bridgewater Associates, LP

$19.6 Billion
Q1 2024

A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Legend Biotech Corp stock. As of the latest transaction made, Bridgewater Associates, LP holds 208,900 shares of LEGN stock, worth $8.36 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

208,900

Previous 330,091 36.71%

Holding current value

$8.36 Million

Previous $19.9 Million 41.0%

% of portfolio

0.06%

Previous 0.11%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$55.06 - $69.99 $6.67 Million - $8.48 Million	-121,191 Reduced 36.71%	208,900 $11.7 Million
Q4 2023 Feb 14, 2024	SELL	$57.25 - $69.74 $1.26 Million - $1.53 Million	-22,000 Reduced 6.25%	330,091 $19.9 Million
Q3 2023 Nov 13, 2023	BUY	$63.16 - $76.5 $922,514 - $1.12 Million	14,606 Added 4.33%	352,091 $23.6 Million
Q2 2023 Aug 11, 2023	BUY	$46.28 - $75.01 $2.71 Million - $4.39 Million	58,543 Added 20.99%	337,485 $23.3 Million
Q1 2023 May 12, 2023	SELL	$43.42 - $57.37 $7.58 Million - $10 Million	-174,681 Reduced 38.51%	278,942 $13.5 Million

Q4 2022 Feb 13, 2023	SELL	$38.8 - $55.46 $6.35 Million - $9.08 Million	-163,727 Reduced 26.52%	453,623 $22.6 Million
Q3 2022 Nov 10, 2022	BUY	$38.15 - $57.1 $1.75 Million - $2.61 Million	45,763 Added 8.01%	617,350 $25.2 Million
Q2 2022 Aug 11, 2022	BUY	$33.54 - $55.0 $951,898 - $1.56 Million	28,381 Added 5.22%	571,587 $31.4 Million
Q1 2022 May 13, 2022	BUY	$31.02 - $48.18 $13.2 Million - $20.6 Million	427,047 Added 367.64%	543,206 $19.7 Million
Q4 2021 Feb 14, 2022	BUY	$41.14 - $56.98 $4.78 Million - $6.62 Million	116,159 New	116,159 $5.41 Million

Others Institutions Holding LEGN

# of Institutions

213

Shares Held

63.6M

Call Options Held

1.09M

Put Options Held

525K

View Full List

About Legend Biotech Corp

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $6.7B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

More about LEGN

Track Ray Dalio's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.

Account